Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PCV24 in Individuals Aged 2 Months and Older
NCT07600983Phase 2Recruiting
- Sponsor
- CanSino Biologics Inc.
- Start
- May 2026
- Primary completion
- Nov 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) in Streptococcus pneumoniae infection, sponsored by CanSino Biologics Inc.. Started May 2026; status: recruiting.
02
Drugs
24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid)
03
Conditions
Streptococcus pneumoniae infection
Beyond the preview
Go deeper on NCT07600983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07600983.